Pfizer (NYSE:PFE) and BioNTech's (NASDAQ:BNTX) COVID-19 vaccine showed 73.2% efficacy in children ages six months through four years of age in a phase 2/3 trial.
The company said the results reinforcing previously reported interim vaccine efficacy data collected in
